EZH2 INHIBITION ENHANCES T CELL IMMUNOTHERAPIES BY INDUCING LYMPHOMA IMMUNOGENICITY AND IMPROVING T CELL FUNCTION (CUT&RUN)
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 16 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 16 samples: 5 × PDX_DLBCL-EZB_vehicle_H3K27me3CnR vs 5 × PDX_DLBCL-EZB_tazemetostat_H3K27me3CnR vs 3 × tFL-P6_cellLine_DMSO_H3K27me3CnR vs 3 × tFL-P6_cellLine_tazemetostat_H3K27me3CnRGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionCancer cell · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE278481_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1167338 and SRA study SRP535828. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 16 samples.
How we read this: 4 replicated groups read from 16 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8547459 tFL-P6_cellLine_DMSO_H3K27me3CnR_repl1 tFL-P6_cellLine_DMSO_H3…
- GSM8547460 tFL-P6_cellLine_DMSO_H3K27me3CnR_repl2 tFL-P6_cellLine_DMSO_H3…
- GSM8547461 tFL-P6_cellLine_DMSO_H3K27me3CnR_repl3 tFL-P6_cellLine_DMSO_H3…
- GSM8547462 tFL-P6_cellLine_tazemetostat_H3K27me3CnR_repl1 tFL-P6_cellLine_tazemet…
- GSM8547463 tFL-P6_cellLine_tazemetostat_H3K27me3CnR_repl2 tFL-P6_cellLine_tazemet…
- GSM8547464 tFL-P6_cellLine_tazemetostat_H3K27me3CnR_repl3 tFL-P6_cellLine_tazemet…
- GSM8547465 PDX_DLBCL-EZB_vehicle_H3K27me3CnR_repl1 PDX_DLBCL-EZB_vehicle_H…
- GSM8547466 PDX_DLBCL-EZB_vehicle_H3K27me3CnR_repl2 PDX_DLBCL-EZB_vehicle_H…
- GSM8547467 PDX_DLBCL-EZB_vehicle_H3K27me3CnR_repl3 PDX_DLBCL-EZB_vehicle_H…
- GSM8547468 PDX_DLBCL-EZB_vehicle_H3K27me3CnR_repl4 PDX_DLBCL-EZB_vehicle_H…
- GSM8547469 PDX_DLBCL-EZB_vehicle_H3K27me3CnR_repl5 PDX_DLBCL-EZB_vehicle_H…
- GSM8547470 PDX_DLBCL-EZB_tazemetostat_H3K27me3CnR_repl1 PDX_DLBCL-EZB_tazemetos…
- GSM8547471 PDX_DLBCL-EZB_tazemetostat_H3K27me3CnR_repl2 PDX_DLBCL-EZB_tazemetos…
- GSM8547472 PDX_DLBCL-EZB_tazemetostat_H3K27me3CnR_repl3 PDX_DLBCL-EZB_tazemetos…
- GSM8547473 PDX_DLBCL-EZB_tazemetostat_H3K27me3CnR_repl4 PDX_DLBCL-EZB_tazemetos…
- GSM8547474 PDX_DLBCL-EZB_tazemetostat_H3K27me3CnR_repl5 PDX_DLBCL-EZB_tazemetos…
- GSE261746 EZH2 INHIBITION ENHANCES T CELL IMMUNOTHERAPIES BY INDUCING LYMPHOMA IMMUNOGENICITY AND IMPROVING T CELL FUNCTION 54 samples shares enhances, inducing, lymphoma, ezh2, immunotherapies, immunogenicity
- GSE255548 EZH2 INHIBITION ENHANCES T CELL IMMUNOTHERAPIES BY INDUCING LYMPHOMA IMMUNOGENICITY AND IMPROVING T CELL FUNCTION (RNA-Seq) 35 samples shares enhances, inducing, lymphoma, ezh2, immunotherapies, immunogenicity
- GSE218716 EZH2 gain-of-function mutations distort H3K27me3 landscapes and transform transcriptional responses to PRC2 inhibition [ChIP-Seq/Cut&Run-Seq] 156 samples shares ezh2, cut, run
- GSE71225 EZH2 inhibition as a targeted therapy for H3K27M mutant pediatric gliomas [ChIP-seq] 13 samples shares ezh2
- GSE218717 EZH2 gain-of-function mutations distort H3K27me3 landscapes and transform transcriptional responses to PRC2 inhibition. 244 samples shares ezh2
- GSE261554 Targeting Vdac2 overcomes immunotherapy resistance by inducing tumor cell death and inflammation 180 samples shares inducing
- GSE266298 Epigenetic changes by EZH2 inhibition increase translocations in B cells with high AID activity or DNA repair deficiency 130 samples shares ezh2
- GSE285764 Single Alkyl Phosphonate Modification of the siRNA Backbone in the Seed Region Enhances Specificity and Therapeutic Profile 110 samples shares enhances
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.